Itschak Lamensdorf,
CEO
Dr. Lamensdorf founded Pharmaseed in 2003, and has been responsible for its scientific course of expansion, national and international collaborations and staff excellence. Dr. Lamensdorf was the CEO of Thrombotech a company developing new technology for treatment of stroke leading the company to initiation of a phase IIa study (from an idea stage company). In addition, he led the development of medical technologies for treatment of cancer and skin atrophy. Dr. Lamensdorf holds a Ph.D. in Pharmacology from the Faculty of Medicine of the Technion, Israel Institute of Technology, and a B.S. and M.Sc. in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School. He held postdoctoral positions at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science.
|
|
|
